Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 4/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159126 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL29358853 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL31474793 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL9242218 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL8695992 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL23733547 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL30997435 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL10620393 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL9242204 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 | |
| SCHEMBL29349982 | 1.00 | DPP4 (0.48) | DPP4MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3624832-B1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE | INST NAT SANTE RECH MED (FR) | 2025-08-20 | — | — | EP | claimed |
| US-20240287509-A1 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE (CN) | 2024-08-29 | — | — | US | claimed |
| EP-4056168-A9 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | Shanghai Jiaotong University School of Medicine (CN) | 2022-11-23 | — | — | EP | claimed |
| EP-4056168-A1 | NANO COMPLEX FOR TARGETED REPAIRING OF NEUROVASCULAR LESION, AND PREPARATION AND USE THEREOF | Shanghai Jiaotong University School of Medicine (CN) | 2022-09-14 | — | — | EP | claimed |
| EP-4748438-A2 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES | Cedars-Sinai Medical Center (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137751-A1 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES | CEDARS-SINAI MEDICAL CENTER (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260083672-A1 | FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMANS | 4TEEN4 Pharmaceuticals GmbH (DE) | 2026-03-26 | — | — | US | disclosed |
| EP-4194001-B1 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY | CEDARS SINAI MEDICAL CENTER (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12551526-B2 | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes | CEDARS-SINAI MEDICAL CENTER (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4687942-A1 | DPP3 INHIBITOR FOR MYOCARDIAL PROTECTION AND PREVENTION OF MYOCARDIAL INJURY IN CRITICALLY ILL PATIENTS WITH BLOOD PRESSURE DECLINE | 4TEEN4 Pharmaceuticals GmbH (DE) | 2026-02-11 | — | — | EP | disclosed |
| US-20260028423-A1 | PREDICTION OF AN INCREASE OF DPP3 IN A PATIENT WITH SEPTIC SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2026-01-29 | — | — | US | disclosed |
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| CN-114984197-A | Application of tenecteplase in preparing pharmaceutical composition for treating acute ischemic stroke | 江苏丰华生物制药有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220211798-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-07-07 | — | — | US | disclosed |
| EP-4021571-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-07-06 | — | — | EP | disclosed |
| CN-114441702-A | Method for detecting I, II type rhTNK-tPA content | 广州铭康生物工程有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-114395025-A | Paralichthys atranus antifreeze protein gene ep-afp and application thereof | 昆明学院 | 2022-04-26 | — | — | CN | disclosed |
| US-20130267681-A1 | CHEMICAL LIGATION BY RING OPENING OF OXO-THIOMORPHOLINES | THE UNIVERSITY OF READING (GB) | 2013-10-10 | — | — | US | disclosed |
| EP-0483429-A1 | Biodegradable polymer compositions | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-05-06 | — | — | EP | disclosed |
| US-4999417-A | Drug carriers for controlled release | NOVA PHARMACEUTICAL CORPORATION (US) | 1991-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083672-A1 | FORMULATIONS AND DOSAGE AMOUNTS FOR ADMINISTERING AN ANTI-DPP3 ANTIBODY OR FRAGMENT THEREOF TO HUMANS | DPP3, DPP4, TREH | DPP4 2/4885MME 144/4885ACE 147/4885 |
| US-20220211798-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF | DPP3, ACE, FABP3 | DPP4 8/4885MME 38/4885ACE 2/4885 |
| US-20260028423-A1 | PREDICTION OF AN INCREASE OF DPP3 IN A PATIENT WITH SEPTIC SHOCK | DPP3, DPP4, DPP7 | DPP4 2/4885MME 186/4885ACE 76/4885 |
| US-20260137751-A1 | ENTERICALLY DELIVERED BITTER OLIGOPEPTIDES FOR THE TREATMENT FOR TYPE 2 DIABETES | GLP1R, GIPR, NPY2R | DPP4 161/4885MME 2644/4885ACE 3710/4885 |
| US-12551526-B2 | Enterically delivered bitter oligopeptides for the treatment for type 2 diabetes | GLP1R, GIPR, NPY2R | DPP4 174/4885MME 3513/4885ACE 4643/4885 |
| US-20130267681-A1 | CHEMICAL LIGATION BY RING OPENING OF OXO-THIOMORPHOLINES | PTMS, DNPEP, TAC3 | DPP4 231/4885MME 402/4885ACE 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.